Phenylephrine Hydrochloride

Drug Hikma Pharmaceuticals USA
Total Payments
$388,249
Transactions
100
Doctors
1
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2024 $33,627 13 0
2023 $45,490 14 0
2022 $118,014 9 0
2021 $18,750 12 0
2020 $30,796 12 1
2019 $26,261 13 1
2018 $115,312 27 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $379,475 96 97.7%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,622 3 2.0%
Consulting Fee $1,152 1 0.3%

Payments by Type

Research
$379,475
96 transactions
General
$8,774
4 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Phase 4 Open Label Pediatric Study to Determine Pharmacokinetics of Phenylephrine Hikma Pharmaceuticals USA $264,163 1
Phase 4 Open Label Pediatric Study to Determine Pharmacokinetics of Phenylephrine West-Ward Pharmaceuticals $115,312 0

Top Doctors Receiving Payments for Phenylephrine Hydrochloride

Doctor Specialty Location Total Records
Unknown Washington, DC $385,977 98
, M.D Anesthesiology Scottsdale, AZ $2,272 2

About Phenylephrine Hydrochloride

Phenylephrine Hydrochloride is a drug associated with $388,249 in payments to 1 healthcare providers, recorded across 100 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.

Payment data is available from 2018 to 2024. In 2024, $33,627 was paid across 13 transactions to 0 doctors.

The most common payment nature for Phenylephrine Hydrochloride is "Unspecified" ($379,475, 97.7% of total).

Phenylephrine Hydrochloride is associated with 2 research studies, including "Phase 4 Open Label Pediatric Study to Determine Pharmacokinetics of Phenylephrine" ($264,163).